Lubbock, TX, United States
Lubbock, TX, United States

Time filter

Source Type

Cancer vaccines were demonstrated to be promising strategies for cancer treatment; however these strategies are limited by the paucity of target antigens that provoke an effective immune response. The Inventors of the present patent application propose that sperm fibrous sheet proteins constitute a new class of potential antigens for use in the development of effective, durable cancer vaccines. This hypothesis is supported by the expression of the sperm fibrous sheath protein, known as Sperm protein 17 (Sp17), which is detected in tumors of unrelated histological origin. It has the ability to induce T-cell based immune responses. The expression of the Sperm protein 17 (Sp17) in tumors of unrelated histological origin, and its natural localization in the human sperm fibrous sheath (FS), led the Inventors to hypothesize that FS proteins might represent a new potential class of target antigens useful for developing cancer vaccines, as well as diagnostic and therapeutic treatments.


The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter or a constitutive promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. The therapeutic agent may be, for example, Interleukin 10 (IL10), Forkhead box P3 (FOXP3), or a member of a transforming growth factor beta 1 (TGF1) signaling pathway, such as SMAD3.


The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that the promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body. The disease-specific promoter may be the promoter of the LOX1 gene. The therapeutic agent may be Interleukin 10 (IL10).


This invention provides methods and compositions for the treatment and/or prevention of cancer, including solid malignancies and hematologic malignancies. In particular, the present invention relates to immunotherapy using antigen-presenting cells loaded with tumor associated peptide antigens (TAPAs). If a subject expresses at least one tumor-associated antigen, the subject can be treated by antigen-presenting cells (e.g., dendritic cells) loaded with at least one tumor-associated peptide antigen derived from the tumor-associated antigen (s) expressed by the subject. This personalized immunotherapy induces or enhances immune responses to cells that express tumor-associated antigen(s).


The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that any disease specific promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body. The disease-specific promoter may be the promoter of the LOX1 gene. The invention also provides for constitutive promoters. The therapeutic agent may be, for example, Interleukin 10 (IL10) or a member of a transforming growth factor beta 1 (TGF1) signaling pathway, such as mothers against decapentaplegic homolog 3 (SMAD3).


Trademark
Kiromic Inc. | Date: 2015-02-06

Cardiovascular treatment preparations.


Trademark
Kiromic Inc. | Date: 2014-12-05

Mouthwash.


Trademark
Kiromic Inc. | Date: 2016-11-01

Proteins and peptides in raw material form for scientific and medical research. Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing.


Trademark
Kiromic Inc. | Date: 2016-11-01

Proteins and Peptides in raw material form for scientific and medical research. Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing.


Loading Kiromic Inc. collaborators
Loading Kiromic Inc. collaborators